BPMC Quote, Trading Chart, Blueprint Medicines Corporation
home / stock / bpmc / bpmc quote
$82.78 Last:
-0.01% Change Percent:
$82.59 Open:
$82.78 Previous Close:
$83.795 High:
$81.91 Low:
1,394,822 Volume:
06/21/2021 04:42:41 am Last Trade Date Time:
Quotes are delayed by 15 to 20 minutes.
BPMC Last Five Trading Days
| Stock Date | Open Price | Close Price | High | Low | Volume |
|---|---|---|---|---|---|
| 2021-06-21 | 82.59 | 82.78 | 83.795 | 81.91 | 1,394,822 |
| 2021-06-18 | 83.26 | 82.79 | 83.66 | 81.38 | 1,169,479 |
| 2021-06-17 | 84.87 | 83.53 | 87.98 | 83.03 | 1,381,917 |
| 2021-06-16 | 84.52 | 85.56 | 87.8899 | 80.57 | 1,900,797 |
| 2021-06-15 | 86.42 | 84.27 | 86.8514 | 83.78 | 327,562 |
| 2021-06-14 | 87.25 | 86.29 | 91.73 | 86.14 | 546,747 |
| 2021-06-11 | 85.3 | 86.9 | 87.21 | 84 | 650,875 |
| 2021-06-10 | 83 | 84.11 | 84.44 | 82.1765 | 1,651,842 |
| 2021-06-09 | 86.31 | 82.97 | 86.98 | 82.76 | 538,381 |
| 2021-06-08 | 85.33 | 85.43 | 86.22 | 83.02 | 557,830 |
| 2021-06-07 | 84.99 | 84.75 | 85.78 | 83.99 | 1,857,997 |
| 2021-06-04 | 87.27 | 84.72 | 87.34 | 84.45 | 418,537 |
| 2021-06-03 | 86.69 | 86.1 | 87.06 | 85.415 | 253,401 |
| 2021-06-02 | 89.03 | 87.13 | 89.75 | 86.34 | 717,080 |
| 2021-06-01 | 91.67 | 89.16 | 92.1 | 89.09 | 334,822 |
| 2021-05-31 | 94.13 | 91.35 | 96.015 | 91.21 | 555,435 |
| 2021-05-28 | 94.13 | 91.35 | 96.015 | 91.21 | 552,606 |
| 2021-05-27 | 96.9 | 93.36 | 97.26 | 92.92 | 425,071 |
| 2021-05-26 | 96.08 | 96.32 | 97.29 | 95 | 197,034 |
| 2021-05-25 | 95.71 | 95.4 | 96.52 | 94.445 | 237,183 |
Blueprint Medicines Corporation Company Name:
BPMC Stock Symbol:
NASDAQ Market:
Blueprint Medicines Corporation Website:
News, Short Squeeze, Breakout and More Instantly...
-
FDA Approves Blueprint Medicines' AYVAKIT™ (avapritinib) for the Treatment of Adults with Advanced Systemic Mastocytosis -- First precision therapy that specifically targets the primary driver of the disease -- -- Durable clinical responses, including complete remissi...
-
Blueprint Medicines Presents ARROW Trial Data for GAVRETO® (pralsetinib) Highlighting Durable Clinical Activity in Patients with Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer and Other Advanced Solid Tumors -- 88% ORR and median duration of response not reached ...
-
Blueprint Medicines Appoints Percy Carter, MBA, Ph.D., as Chief Scientific Officer PR Newswire CAMBRIDGE, Mass. , May 17, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the appointment of Percy Carter , MBA, Ph.D., as...